Insider Transactions in Q2 2023 at Evelo Biosciences, Inc. (EVLO)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 23
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
22,571
-7.92%
|
$0
$0.14 P/Share
|
|
May 08
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
3,537
-5.7%
|
$0
$0.13 P/Share
|
|
May 08
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
38,531
-29.64%
|
$0
$0.13 P/Share
|
|
May 08
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
68,014
-19.26%
|
$0
$0.13 P/Share
|
|
May 08
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
66,730
-40.63%
|
$0
$0.13 P/Share
|
|
May 07
2023
|
Duncan Mc Hale Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+44.18%
|
-
|
|
May 07
2023
|
Mark Bodmer CSO, President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
132,500
+27.28%
|
-
|
|
May 07
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
23,437
+27.42%
|
-
|
|
May 07
2023
|
Marella Thorell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+50.0%
|
-
|